Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Late-Stage Pipeline

67%

2 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 3
2(66.7%)
Phase 2
1(33.3%)
3Total
Phase 3(2)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT01431599Phase 2Unknown

Short-course Preoperative Chemoradiotherapy for Rectal Cancer

Role: lead

NCT02440191Phase 3Unknown

3DCRT vs. IMRT in Early Breast Cancer

Role: lead

NCT02484040Phase 3Unknown

Two-week Course Versus Conventionally Fractionated Chemoradiotherapy in Rectal Cancer

Role: lead

All 3 trials loaded